Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Oncotelic Therapeutics, Inc.

OTLC · OTC · CIK 0000908259 · Healthcare · Biotechnology

INSIDER SIGNAL

42.8 / 100

2 buyers · 7 purchase transaction lines · $37.7K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+4.2 / 25
Role+13.0 / 20
Recency+1.6 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: CHAIRMAN AND CEO (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION97%Largest buyer: Trieu Vuong · $36.7K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-06-15–2026-06-24

Roles in the peak window: CFO, CHAIRMAN AND CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Trieu VuongCHAIRMAN AND CEO
●●●●●●
Shah Amit B.CFO
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

42.8 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 43.1
  2. 43.0
  3. 42.9
  4. 42.8
  5. 42.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

7Purchases
0Sales
0Other Form 4 lines
4SEC filings · 365 days
BUYING7 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-33.3%
3M
-33.3%
6M
-33.3%
12M
-77.8%

Volatility & liquidity

Volatility
193.3%
Beta
—
Avg daily value
USD 5,775

Valuation

Market cap
USD 9.2M
P/E
0.0×

Fundamentals

Profit margin
—
ROE
94.9%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-13 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
15,874
Previous report
13,144
Avg daily volume
869,558
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-01Trieu VuongPurchase (P)Common Stock240,000USD 0.04USD 9,600SEC filing ↗
2026-06-24Trieu VuongPurchase (P)Common Stock115,000USD 0.05USD 5,750SEC filing ↗
2026-06-23Trieu VuongPurchase (P)Common Stock75,000USD 0.05USD 3,750SEC filing ↗
2026-06-22Trieu VuongPurchase (P)Common Stock65,000USD 0.05USD 3,250SEC filing ↗
2026-06-22Shah Amit B.Purchase (P)Common Stock20,000USD 0.05USD 1,000SEC filing ↗
2026-06-17Trieu VuongPurchase (P)Common Stock239,759USD 0.04USD 9,590SEC filing ↗
2026-06-15Trieu VuongPurchase (P)Common Stock96,000USD 0.05USD 4,800SEC filing ↗
2025-07-10Trieu VuongPurchase (P)Common Stock104,000USD 0.01USD 1,040SEC filing ↗
2025-07-09Trieu VuongPurchase (P)Common Stock1USD 0.01USD 0SEC filing ↗
2025-07-08Trieu VuongPurchase (P)Common Stock94,736USD 0.01USD 947SEC filing ↗
2025-01-31Trieu VuongPurchase (P)Common Stock63,775USD 0.03USD 1,913SEC filing ↗
2025-01-30Trieu VuongPurchase (P)Common Stock100,003USD 0.03USD 3,000SEC filing ↗
2025-01-29Trieu VuongPurchase (P)Common Stock183,066USD 0.03USD 5,492SEC filing ↗
2024-11-22Trieu VuongPurchase (P)Common Stock298,499USD 0.03USD 8,955SEC filing ↗
2024-08-23Trieu VuongPurchase (P)Common Stock500,000USD 0.02USD 10,000SEC filing ↗

Form 4 evidence

7 transaction lines in the latest 365-day window; 40 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-01Trieu VuongPurchase (P)Common Stock240,000USD 0.04USD 9,600SEC filing ↗
2026-06-24Trieu VuongPurchase (P)Common Stock115,000USD 0.05USD 5,750SEC filing ↗
2026-06-23Trieu VuongPurchase (P)Common Stock75,000USD 0.05USD 3,750SEC filing ↗
Show recent Form 4 evidence (7 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-01Trieu VuongPurchase (P)Common Stock240,000USD 0.04USD 9,600SEC filing ↗
2026-06-24Trieu VuongPurchase (P)Common Stock115,000USD 0.05USD 5,750SEC filing ↗
2026-06-23Trieu VuongPurchase (P)Common Stock75,000USD 0.05USD 3,750SEC filing ↗
2026-06-22Trieu VuongPurchase (P)Common Stock65,000USD 0.05USD 3,250SEC filing ↗
2026-06-22Shah Amit B.Purchase (P)Common Stock20,000USD 0.05USD 1,000SEC filing ↗
2026-06-17Trieu VuongPurchase (P)Common Stock239,759USD 0.04USD 9,590SEC filing ↗
2026-06-15Trieu VuongPurchase (P)Common Stock96,000USD 0.05USD 4,800SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerOTLC
CIK0000908259
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeOTC

Data coverage

Local Form 4 history40 transaction lines from 2020-03-26 to 2026-07-01
31 P purchase lines · 0 S sale lines · 9 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.